Generic Name and Formulations:
Amoxapine 25mg, 50mg, 100mg, 150mg; tabs.
Indications for Amoxapine:
Depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. Depression accompanied by anxiety or agitation.
Initially 50mg 2–3 times daily; may increase to 100mg 2–3 times daily by the end of the first week. May increase above 300mg/day if dose has been ineffective for a period of at least 2 weeks. Maintenance: when effective dosage established, may give as single dose at bedtime (max 300mg). Elderly: initially 25mg 2–3 times daily; may increase by the end of the first week to 50mg 2–3 times daily. May increase carefully up to 300mg/day if necessary.
Within 14 days of MAOIs. During acute recovery phase following MI.
Monitor for clinical worsening, suicidality, and unusual changes in behavior, esp. during initial few months of treatment and during dose changes. Screen for bipolar disorder prior to initiating therapy. Urinary retention. Angle-closure glaucoma. Increased intraocular pressure. Cardiovascular disorders (monitor closely). Seizure disorders. Discontinue if rash, fever, tardive dyskinesia or neuroleptic malignant syndrome develop. Write ℞ for smallest practical amount. Pregnancy (Cat.C). Nursing mothers.
During or within 5 weeks of fluoxetine. Hyperpyretic crises, severe convulsions, and death with MAOIs (see Contraindications). Potentiates alcohol, barbiturates, other CNS depressants. Paralytic ileus with anticholinergics. Monitor serum levels with CYP450 2D6 inhibitors (eg, quinidine, cimetidine, phenothiazines, propafenone, flecainide, others: see literature). Caution with concomitant electroshock therapy.
Drowsiness, dry mouth, constipation, blurred vision, CNS effects (eg, anxiety, insomnia, restlessness, nervousness, palpitations, tremors, confusion, excitement, nightmares, ataxia, alterations in EEG patterns), edema, rash, elevated prolactin levels, nausea, dizziness, headache, fatigue, weakness, excessive appetite, increased perspiration.
Formerly known under the brand name Asendin.
Tabs 25mg, 50mg, 100mg—100; 150mg—30
Psychiatry Advisor Articles
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV
- Maintenance rTMS for Treatment-Resistant Depression
- New Study Compares Opioid Dependence Relapse Treatments
- Increase Use of Nursing Home for Patients With Cognitive Impairment Category
- Venlafaxine XR Safe, Effective in Treating Generalized Anxiety Disorder